Ace the SCDM CCDM Exam Preparation with Exams Solutions Realistic Practice Tests
About CCDM exam, BraindumpQuiz has a great sound quality, will be the most trusted sources. Feedback from the thousands of registration department, a large number of in-depth analysis, we are in a position to determine which supplier will provide you with the latest and the best CCDM practice questions. The BraindumpQuiz SCDM CCDM Training Materials are constantly being updated and modified, has the highest SCDM CCDM training experience. If you want to pass the exam, please using our BraindumpQuiz SCDM CCDM exam training materials. BraindumpQuiz SCDM CCDM Add to your shopping cart, it will let you see unexpected results.
SCDM CCDM Exam Syllabus Topics:
Topic
Details
Topic 1
Topic 2
Topic 3
Topic 4
Topic 5
Practice Test SCDM CCDM Fee | CCDM Test Registration
If you are working all the time, and you hardly find any time to prepare for the CCDM exam, then BraindumpQuiz present the smart way to CCDM exam prep for the exam. You can always prepare for the CCDM test whenever you find free time with the help of our CCDM Pdf Dumps. We have curated all the CCDM questions and answers that you can view the exam SCDM CCDM PDF brain dumps and prepare for the exam. We guarantee that you will be able to pass the CCDM in the first attempt.
SCDM Certified Clinical Data Manager Sample Questions (Q24-Q29):
NEW QUESTION # 24
Every database lock should follow documented approval of which stakeholders?
Answer: B
Explanation:
According to the Good Clinical Data Management Practices (GCDMP), the database lock (DBL) process signifies the formal closure of the clinical trial database, ensuring that no further changes can be made to the data before statistical analysis. This process must be documented, controlled, and approved by key study stakeholders to ensure data accuracy, completeness, and readiness for analysis.
The GCDMP specifies that database lock should occur only after all data cleaning, discrepancy resolution, and reconciliation activities are complete. The lock authorization typically requires the approval of the Clinical/Scientific Representative (to confirm clinical completeness), the Data Manager (to confirm data integrity and query closure), and the Biostatistician (to confirm readiness for statistical analysis).
This tri-party approval ensures that the database reflects final, verified data consistent with the clinical protocol, and that the statistical analysis dataset derived from the database is accurate and auditable. The approval process is documented via a Database Lock Authorization Form or Sign-off Log, which becomes part of the permanent trial master file (TMF).
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Lock and Archiving, Section 7.1 - Lock Procedures and Approvals ICH E6 (R2) GCP, Section 5.5.3 - Data Handling and Record Keeping FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Section on Database Closure
NEW QUESTION # 25
A Data Manager is importing lab data for a study. The lab data and the associated audit trail is kept at the central lab. What is necessary to maintain traceability of the transferred data at the Data Manager's location?
Answer: A
Explanation:
Maintaining traceability of external data imports (such as laboratory results) is a fundamental principle of clinical data management. According to the GCDMP (Chapter: External Data Transfers and Integration), Data Managers must retain an unaltered copy of the raw data exactly as received from the vendor.
This archived version serves as a reference for:
Data provenance verification,
Audit trail review, and
Discrepancy resolution between vendor and study database.
Since the central lab maintains its own audit trail, the Data Manager's responsibility is to preserve the original data transmission file before applying transformations, merges, or validations.
Options A, C, and D describe procedural safeguards but do not meet the regulatory requirement of traceable data lineage. Only option B (Maintaining a copy of the data as received) ensures compliance with ICH E6(R2) and FDA 21 CFR Part 11 standards for data traceability and integrity.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: External Data Transfers and Integration, Section 5.2 - Data Traceability and Version Control ICH E6(R2) GCP, Section 5.5.3 - Data Integrity and Source Data Verification FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.4 - Source Data Traceability and Archiving
NEW QUESTION # 26
In a study, data are key entered by one person after which a second person enters the data without knowledge of or seeing the values entered by the first. The second person is notified during entry if an entered value differs from first entry and the second person's decision is retained as the correct value. Which type of entry is being used?
Answer: A
Explanation:
The described process is Blind Verification, also known as double data entry with blind verification. In this method, two independent operators enter the same data. The second operator is blinded to the first entry to avoid bias. When discrepancies arise, the system flags them for review, and the second entry (or an adjudicated value) is retained as the correct one.
According to GCDMP (Chapter: Data Entry and Data Tracking), blind double data entry is used primarily in paper-based studies to minimize transcription errors and ensure data accuracy.
Single entry (D): Only one operator enters data.
Manual review (B): Involves post-entry checking, not during entry.
Third-party compare (C): Used for reconciling external data sources, not CRF data.
Hence, option A (Blind verification) is the correct and CCDM-defined process.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Entry and Data Tracking, Section 5.1 - Double Data Entry and Verification Methods ICH E6(R2) GCP, Section 5.5.3 - Data Entry and Verification Controls FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.2 - Data Accuracy and Verification
NEW QUESTION # 27
Electronic submission standards require that an individual subject's complete CRF should be provided as what type of file:
Answer: C
Explanation:
Electronic submission standards, as established by FDA, CDISC, and ICH, require that an individual subject's complete Case Report Form (CRF) be submitted as a Portable Document Format (.pdf) file. The PDF format is universally recognized and accepted because it ensures that the structure, format, and visual fidelity of the CRF are preserved exactly as originally designed, regardless of software or hardware environment.
According to the FDA Guidance for Industry: Providing Regulatory Submissions in Electronic Format (2006) and CDISC SDTM standards, sponsors must include a subject-level CRF in PDF form for each participant in the submission dataset. This requirement ensures that reviewers can trace data points from analysis datasets back to their source entries in the CRF, fulfilling the principles of data traceability and transparency.
The Good Clinical Data Management Practices (GCDMP) also support this requirement, emphasizing that CRF archiving should maintain readability and regulatory accessibility. Formats like RTF, DOCX, or SAS datasets are not acceptable substitutes for regulatory CRF submission because they may alter formatting, structure, or introduce modifiable content, violating FDA data integrity principles.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Archiving and Submission FDA Guidance for Industry: Providing Regulatory Submissions in Electronic Format, April 2006 CDISC SDTM Implementation Guide, Section 5.3 - CRF Representation and Traceability
NEW QUESTION # 28
QA is conducting an audit on a study for ophthalmology which is ready for lock. Inconsistencies are found between the database and the source. Of the identified fields containing potential data errors, which fields are considered critical for this particular study?
Answer: A
Explanation:
In an ophthalmology clinical study, data criticality is determined by how directly a data element affects safety evaluation, efficacy assessment, and regulatory decision-making. According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Validation and Cleaning), critical data fields are those that:
Have a direct impact on the primary and secondary endpoints, or
Are essential for safety interpretation and adverse event causality assessment.
Among the listed options, Concomitant Medications (Option B) are considered critical data for ophthalmology studies. This is because many ocular treatments and investigational products can interact with systemic or topical medications, potentially affecting ocular response, intraocular pressure, corneal healing, or visual function outcomes. Any inconsistency in concomitant medication data could directly influence safety conclusions or efficacy interpretations.
Other options, while important, are less critical for this study type:
Subject Identifier (A) is essential for data traceability and audit purposes but is not directly related to safety or efficacy outcomes.
Weight (C) may be relevant in dose-dependent drug trials but is rarely a pivotal variable in ophthalmology, where local administration (eye drops, intraocular injections) is common.
Medical History (D) provides contextual background but does not have the same immediate impact on endpoint analysis as current concomitant treatments that can confound the therapeutic effect or cause ocular adverse events.
Per GCDMP and ICH E6 (R2) GCP guidelines, data validation plans must define critical data fields during study setup, reflecting therapeutic area-specific priorities. For ophthalmology, concomitant medications, ocular assessments (visual acuity, intraocular pressure, retinal thickness, etc.), and adverse events are typically designated as critical fields requiring heightened validation, source verification, and reconciliation accuracy before database lock.
Thus, when QA identifies discrepancies between the CRF and source, the Concomitant Medications field (Option B) is the most critical to address immediately to ensure clinical and regulatory data integrity.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.4 - Critical Data Fields and Data Validation Prioritization ICH E6 (R2) Good Clinical Practice, Section 5.18 - Monitoring and Source Data Verification FDA Guidance for Industry: Oversight of Clinical Investigations - A Risk-Based Approach to Monitoring, Section 5.3 - Identification of Critical Data and Processes SCDM GCDMP Chapter: Data Quality Assurance and Control - Therapeutic Area-Specific Data Criticality Examples (Ophthalmology Studies)
NEW QUESTION # 29
......
It is exceedingly helpful in attaining a suitable job when qualified with CCDM certification. It is not easy to get the CCDM certification, while certified with which can greatly impact the future of the candidates. Now, please take CCDM practice dumps as your study material, you will pass your exam with CCDM practice materials successfully. CCDM free demo is available for everyone. Our CCDM practice dumps are extremely detailed and complete in all key points which will be in the real test. Believe us and you can easily pass by our CCDM practice dumps.
Practice Test CCDM Fee: https://www.braindumpquiz.com/CCDM-exam-material.html